More on Edwards Lifesciences (EW): Q4 beats on both EPS and revenue as total sales jump 18% Y/Y....


More on Edwards Lifesciences (EW): Q4 beats on both EPS and revenue as total sales jump 18% Y/Y. Net profit also soared by 44% versus the prior year period as revenue improved across the medical-device company's segments - led by sales of transcatheter heart valves - and the period was also boosted by a tax benefit. Looking forward, the company expects to benefit from October's FDA decision to expand the approved use of its Sapien device to include high-risk surgery patients, and the company is investing heavily into that expansion. Shares +0.5% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs